BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 17440161)

  • 41. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin.
    de la Torre A; García-Berrocal MI; Arias F; Mariño A; Valcárcel F; Magallón R; Regueiro CA; Romero J; Zapata I; de la Fuente C; Fernández-Lizarbe E; Vergara G; Belinchón B; Veiras M; Molerón R; Millán I
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):102-10. PubMed ID: 17869446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Phase I study of 5-fluorouracil and l-leucovorin].
    Sasaki T; Ota K; Wakui A; Akazawa S; Ogawa M; Ariyoshi Y; Yura J; Inagaki J; Hoshino A; Abe T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):485-91. PubMed ID: 8452386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
    Petrioli R; Sabatino M; Roviello F; Marrelli D; Nastri G; Marsili S; Correale P; Pozzessere D; Messinese S; De Martino A; Tani F; Marzocca G; Lorenzi M; Civitelli S; Tanzini G; Pinto E; Francini G
    Hepatogastroenterology; 2005; 52(65):1626-30. PubMed ID: 16201130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)].
    Nagata H; Koike A; Kojima T; Ohiwa Y; Miwa M; Inamura Y; Matsumoto K; Suzumura K; Kanemitsu T; Naruse T
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):2049-52. PubMed ID: 8215480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
    Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical effect and characteristics of low dose leucovorin and high dose 5-FU therapy in patients with recurrent gastric cancer--a new method of biochemical modulation].
    Kajiyama Y; Tsurumaru M; Ono Y; Udagawa H; Watanabe G; Suzuki M; Matsuda M; Akiyama H
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1797-801. PubMed ID: 8379672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
    Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
    Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Interim report of JFMC study no. 23--phase III randomized clinical trial on the effectiveness of low-dose cisplatin plus 5-FU as a postoperative adjuvant chemotherapy for advanced gastric cancer].
    Saji S; Toge T; Kurosu Y; Hirata K; Gochi A; Tominaga S; Inokuchi K
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2499-507. PubMed ID: 12506472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
    Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
    Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
    Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
    Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Neoadjuvant chemotherapy for advanced gastric cancer using FLEP therapy].
    Mochizuki F; Fujii M; Kasakura Y; Kochi M; Imai S; Eguchi T; Tsuneda Y; Kanamori N; Kaiga T; Kobayashi M
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1812-5. PubMed ID: 11086418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.